UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 5)*
GREENBRIAR CORPORATION
--------------------------
(Name of Issuer)
Common Stock, par value $0.01 per share
-------------------------------------
(Title of Class of Securities)
393648-10-0
---------------------------
(CUSIP Number)
Sylvia M. Gilley, 4265 Kellway Circle, Addison, Texas 75244
-----------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)
May 24, 1996
-------------------------------
(Date of Event which Requires Filing of this Settlement
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box.
Check the following box if a fee is being paid with the statement. (A fee is not
required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
SCHEDULE 13D
CUSIP No. 393648-10-0 Page 2 of 4 Pages
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Sylvia Gilley (SS# ###-##-####)
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) X
(b)
3 SEC USE ONLY
4 SOURCE OF FUNDS*
PF
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
6 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
7 SOLE VOTING POWER
Number of 536,000
Shares
Beneficially
Owned by
Each
Reporting
Person
With
8 SHARED VOTING POWER
1,044,000
9 SOLE DISPOSITIVE POWER
536,000
10 SHARED DISPOSITIVE POWER
1,044,000
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,044,000
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
29%
<PAGE>
14 TYPE OF REPORTING PERSON*
IN
<PAGE>
Item 1. Security and Issuer.
This statement relates to common stock, par value $0.01 per share of
Greenbriar Corporation (formerly known as Medical Resource Companies of America,
a Nevada corporation) (the "Issuer"), with principal executive offices at 4265
Kellway Circle, Addison, Texas 75244. All share amounts have been adjusted to
reflect a 1 for 5 reverse split of the common stock on December 1, 1995.
Item 2. Identity and Background.
This statement is filed with respect to the acquisition of a Stock Purchase
Warrant to purchase 108,000 unregistered shares of the Issuer's common stock and
to the beneficial ownership of 1,044,000 unregistered shares of the Issuer's
common stock, of which 536,000 shares are held of record by the undersigned and
508,000 shares are held of record by James R. Gilley, as trustee of The April
Trust, a revocable grantor trust of which the undersigned is a beneficiary. The
following information is provided regarding the owner:
(1) No change.
(2) 4265 Kellway Circle, Addison, Texas 75244.
(3) No change.
(d) No change.
(4) No change.
(5) No change.
Item 3. Source and Amounts of Funds or Other Consideration.
The April Trust paid $228,000 of its cash on hand in order to purchase a
warrant to purchase 108,000 shares of common stock, and will have to pay $12.98
per share (total of $1,401,840) in order to exercise the warrants. The Trust
does not currently know the source of funds that will be used to exercise the
warrants.
Item 4. Purpose of Transaction.
The April Trust agreed with Catherine C. Weiss and Innovative Health
Services, Inc. to acquire the warrants in exchange of $228,000 cash ($2.11 per
share). The warrants are exercisable at the current rate of $12.98 per share;
therefore, the total consideration to be paid for each share would be $15.09,
which was the approximate market price of the shares on the date the warrants
were acquired. The Trust is buying the warrants because it believes it will be
advantageous to exercise the warrants and increase its investment in the Common
Stock of the Company.
Other than as set out herein, Mrs. Gilley has no current plans or proposals
which relate or would result in any of the matters listed in Items 4(a) through
4(j), inclusive, of Schedule 13D.
<PAGE>
Item 5. Interest in Securities of the Issuer.
(a) The undersigned owns of record and beneficially 1,044,000 shares
representing 29% of shares outstanding. The spouse of the undersigned
owns, directly and indirectly, a total of 1,918,000 shares of the
Issuer's common stock. Together they own 2,454,000 shares,
representing 68.4% of shares outstanding. Except for the 508,000
shares held in trust, the undersigned and her spouse disclaim any
beneficial ownership in the shares owned of record by the other.
(b) The undersigned has sole power to vote and dispose of 536,000 shares.
(c) Not applicable.
(d) Not applicable.
(e) Not applicable.
Item 6. Contract, Arrangement, Understandings and Relationship with Respect to
Securities of the Issuer.
No change.
Item 7. Material to be Filed as Exhibits.
Warrant Purchase Agreement
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: May 31, 1996 /s/ Sylvia M. Gilley
---------------------
Sylvia M. Gilley
Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001).
<PAGE>
WARRANT PURCHASE AGREEMENT
WARRANT PURCHASE AGREEMENT ("Agreement") dated as of May ___, 1996 by and
between INNOVATIVE HEALTH SERVICES, INC., a Georgia corporation ("Innovative"),
and Catherine C. Weiss ("Weiss") (together the "Selling Warrant Holders") and
April Trust (the "Trust").
W I T N E S S E T H:
WHEREAS, the Selling Warrant Holders are the owners of warrants to purchase
108,000 shares of the Common Stock of Greenbriar Corporation, formerly Medical
Resource Companies of America, a Nevada corporation (the "Company"), currently
at a price of $12.98 per share, and which are more particularly described on the
attached Exhibit "A" hereto (the "Warrants");
WHEREAS, the Selling Warrant Holders desires to sell and the Trust desires
to purchase the Warrants, which are owned by the Selling Warrant Holders, on the
terms and conditions set forth in this Agreement;
NOW, THEREFORE, in consideration of the premises and the mutual covenants,
agreements and provisions contained herein, the parties hereto agree as follows:
1. PURCHASE OF WARRANTS AND CLOSING.
1.1. Purchase of Warrants.
Selling Warrant Holders hereby sell, convey, assign, transfer and
deliver to the Trust the Warrants, including any rights to register shares
of the Company, and deliver to the Trust an assignment of the Warrants,
which Selling Warrant Holders warrants are free and clear of all liens,
security interests, pledges, agreements, claims, charges, options or
encumbrances of any nature whatsoever.
1.2. Consideration.
The purchase price for the Warrants is $228,000 which shall be wire
transfered to ABA#061000256 Acct# 21865321.
2. REPRESENTATIONS AND WARRANTIES OF THE SELLING WARRANT HOLDERS.
The Selling Warrant Holders hereby make the following representations,
warranties and covenants to the Trust:
6
<PAGE>
2.1. Ownership of Warrants.
The Warrants were acquired from FF Partnership, L.P. by Weiss. Weiss
assigned an undivided 50% interest in the Warrants to Joseph L. Durant
which was later contributed to Innovative. Immediately prior to the
purchase and sale of the Warrants, the Selling Warrant Holders were the
true and lawful owner of the Warrants. The Selling Warrant Holders have all
necessary power and authority to execute this Agreement and to sell the
Warrants to the Trust, free and clear of all claims, liens, security
interests, rights of spouses or present or former family members or the
Company, pledges, options, encumbrances and other restrictions of any
nature whatsoever, other than transfer restrictions imposed by applicable
federal securities laws and as contemplated by this Agreement. Other than
this Agreement, there is no agreement between the Selling Warrant Holders
and any other person relating to or restricting the transfer of the
Warrants. On the date hereof, the Trust will acquire good and indefeasible
title to the Warrants free and clear of any restrictions of the type
referred to in this Section 2.1, except as contemplated by this Agreement.
2.2. Brokers and Finders.
None of the Selling Warrant Holders has retained or dealt with any
broker, finder or investment banker in connection with this Agreement or
the transactions contemplated by this Agreement, and no commissions are
owed with respect to.
3. REPRESENTATIONS AND WARRANTIES WITH RESPECT TO THE WARRANTS.
The Trust hereby represents, warrants, and covenants to the Selling Warrant
Holders that:
3.1. Investment Experience and Economic Risk.
The Trust is an experienced investor in unregistered and restricted
securities, has such knowledge and experience in financial or business
matters that it is capable of evaluating the merits and risks of an
investment in the Warrants and, by reason of its financial and business
experience, has the capacity to protect its interests in connection with
such investment. The Trust is financially able to bear the economic risk of
its investment in the Warrants, including the total loss thereof.
3.2. Access to Information.
The Trust has received all information it considers necessary or
appropriate for deciding whether to acquire the Warrants. The Trust further
represents that it has had an opportunity to review any documents regarding
the Company on file with the SEC and to ask questions of and receive
answers from Selling Warrant Holders regarding the business, financial
affairs and other aspects of the Company, and has further had the
opportunity to obtain any other information which it deems necessary to
evaluate the investment or to verify the accuracy of information otherwise
provided.
7
<PAGE>
3.3. Investment Representation.
The Trust acknowledges that it is aware that the Warrants have not
been registered under the Act or qualified under any state securities laws,
in reliance, in part, on the representations and warranties of the Selling
Warrant Holders in this Agreement. The Warrants are acquired by such the
Trust for investment purposes only for its own account and not for sale or
with a view to distribution of all or part of the Warrants.
3.4. Restricted Securities.
The Trust understands that the Warrants are characterized as
"restricted securities" under the federal securities laws inasmuch as they
are acquired from Selling Warrant Holders in a transaction not involving a
public offering and that under such laws and applicable regulations, such
securities may not be resold without registration under the Act except in
certain limited circumstances, and that otherwise the Warrants must be held
indefinitely. In this connection, the Trust represents that it is familiar
with SEC Rule 144, as presently in effect, and the conditions which must be
met in order for that Rule to be available for resale of "restricted
securities."
4. REPRESENTATIONS AND WARRANTIES OF THE TRUST.
The Trust represents, warrants and covenants to the Selling Warrant Holders
that:
4.1. Brokers and Finders.
The Trust has not retained any broker, finder or investment banker in
connection with this Agreement or the transactions contemplated by this
Agreement.
4.2. Assumption Of Obligations.
The Trust agrees to assume all obligations of the warrant holders
under that agreement executed in connection with the S-3 registration of
shares of the Company.
5. COVENANTS OF THE SELLING WARRANT HOLDERS.
5.1. Further Assurances.
The Selling Warrant Holders agrees that they will from time to time,
at the request of the Trust and without further consideration, execute and
deliver such other instruments of conveyance, assignment and transfer and
take such other actions as the Trust may reasonably request in order more
effectively to convey, assign, transfer to and vest in the Trust the
Warrants.
8
<PAGE>
6. MISCELLANEOUS.
6.1. Expenses.
The Trust shall pay its own costs and expenses, and the Selling
Warrant Holders shall pay its own costs and expenses relating to this
Agreement, the negotiations leading up to this Agreement and the
performance of this Agreement.
6.2. Entire Agreement.
This Agreement and the exhibit and assignment delivered pursuant to
this Agreement, contain all of the terms and conditions agreed upon by the
parties relating to the subject matter of this Agreement and supersedes all
prior and contemporaneous agreements, negotiations, correspondence,
undertakings and communications of the parties, oral or written, respect
that subject matter.
6.3. Governing Law.
This Agreement is performable and payment shall be made in Dallas
County, Texas, and shall be governed by, and construed in accordance with,
the laws of the State of Texas.
6.4. Severability.
Any provision of this Agreement which is prohibited or unenforceable
in any jurisdiction shall, as to such jurisdiction, be ineffective to the
extent of such prohibition or unenforceability without invalidating the
remaining provisions hereof or affecting the validity or enforceability of
such provision in any other jurisdiction.
6.5. Waiver, Amendment.
No waiver of any term or condition contained in this Agreement and no
purported amendment of this Agreement shall be effective unless it is
signed by the party against whom enforcement of such waiver or amendment is
sought. The waiver of any term or condition of this Agreement by any party
shall not be construed as a waiver of' any other breach or failure of the
same term or condition, or a waiver of any other term or condition of this
Agreement.
6.6. Assignment.
This Agreement shall inure to the benefit of, and be binding upon, the
respective successors, heirs, personal representatives and assigns of the
parties hereto.
9
<PAGE>
6.7. No Third Party Rights.
This Agreement is made for the benefit of the parties hereto and their
successors, and neither this Agreement nor any provision hereof shall be
construed or deemed to give rise to rights in any other person.
6.8. Counterparts.
This Agreement may be executed in counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the
same Agreement.
6.9. Headings, Gender.
The section headings in this Agreement are inserted for convenience of
reference only and shall not affect the meaning or interpretation of this
Agreement. Gender references in this Agreement shall be deemed to include
the masculine, feminine and neuter, as the context may require.
IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
set forth in the first paragraph of this Agreement.
/s/ Catherine C. Weiss
Catherine C. Weiss
Personally
APRIL TRUST
/s/ James R. Gilley
James R. Gilley
Trustee
INNOVATIVE HEALTH SERVICES, INC.
/s/ Joseph L. Durant
JOSEPH L. DURANT
President
Arthur G. Weiss joins herein solely for purpose of waiver of his rights, if any,
in the Warrants
/s/ Arthur G. Weiss
10
<PAGE>
Exhibit H (to Warrant Purchase Agreement)
MEDICAL RESOURCE COMPANIES OF AMERICA
a Nevada Corporation
STOCK PURCHASE WARRANT
To Purchase 540,000 Shares of Common Stock
Par Value $0.01 per share
March 24, 1993
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE
BEEN ACQUIRED FOR INVESTMENT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS AN
OPINION OF COUNSEL SATISFACTORY TO THE COMPANY SHALL HAVE BEEN RECEIVED BY THE
COMPANY TO THE EFFECT THAT SUCH SALE, TRANSFER OR ASSIGNMENT WILL NOT BE IN
VIOLATION OF THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND
REGULATIONS THEREUNDER, OR APPLICABLE STATE SECURITIES LAWS.
1. Basic Terms. This certifies that, for value received, FFP Partnership,
L.P., a Georgia limited partnership (the "Holder") is entitled, subject to the
terms and conditions of this Warrant, until the expiration date, to purchase
540,000 whole shares of Common Stock, par value $0.01 per share (the "Common
Stock"), of Medical Resource Companies of America, a Nevada corporation (the
"Company") from the Company at the purchase price of $2.64 per share (the
"Purchase Price"), on delivery of this Warrant to the Company with Form of
Election to Purchase in the form of Exhibit A duly executed and payment of the
Purchase Price (in cash or by cashier's check payable to the order of the
Company) for each share purchased. This Warrant shall be exercisable at any
time, in whole or in part, from the date hereof until March 21, 2001.
2. Company's Covenants as to Common Stock. Shares deliverable on the
exercise of this Warrant shall, at delivery, be fully paid and non-assessable,
and free from taxes, liens and charges with respect to their purchase. The
Company shall take any necessary steps to assure that the par value per share of
the Common Stock is at all times equal to or less than the then current Purchase
Price per share of the Common Stock issuable pursuant to this Warrant. The
Company shall at all times reserve and hold available sufficient shares of
Common Stock to satisfy all conversion and purchase rights of outstanding
convertible securities, options and warrants.
3. Method of Exercise; Fractional Shares. The purchase rights represented
by this Warrant are exercisable at the option of the Holder in whole or in part,
from time to time, within
11
<PAGE>
the period above specified; provided, however, that purchase rights are not
exercisable with respect to a fraction of a share of Common Stock. In lieu of
issuing a fraction of a share remaining after exercise of this Warrant as to all
full shares covered hereby, the Company shall either (1) pay therefor cash equal
to the same fraction of the then current Warrant purchase price per share or, at
its option, (2) issue scrip for the fraction, in registered or bearer form
approved by the Board of Directors of the Company, which shall entitle the
Holder to receive a certificate for a full share of Common Stock on surrender of
scrip aggregating a full share. Scrip may become void after a reasonable period
(but not less than six months after the expiration date of this Warrant)
determined by the Board of Directors and specified in the scrip. In case of the
exercise of this Warrant for less than all the shares purchasable, the Company
shall cancel the Warrant and execute and deliver a new Warrant of like tenor and
date for the balance of the shares purchasable. Upon the date of receipt by the
Company of an exercise of the Warrant ("Exercise Date"), the Warrant shall be
deemed to have been exercised as to the number of shares so purchased, and the
person so exercising the Warrant shall become a holder of record of shares of
Common Stock on the Exercise Date.
4. Adjustments of Shares and Purchase Price. The initial number of shares
of Common Stock purchasable upon exercise of this Warrant and the Purchase Price
shall be subject to adjustment from time to time after the date hereof as
follows:
A. In case the Company shall (1) pay a dividend in, or make a
distribution of, Common Stock or of any other interests in the Company
convertible into Common Stock, (2) subdivide its outstanding Common Stock
into a greater number of such Common Stock, or (3) combine its outstanding
Common Stock into a smaller number of such Common Stock, the total number
of shares of Common Stock and the interests in the Company convertible into
Common Stock purchasable upon the exercise of each Warrant outstanding
immediately prior thereto shall be adjusted so that the Holder of any
Warrant thereafter surrendered for the purchase of Common Stock shall be
entitled to receive at the same aggregate Purchase Price the number of
shares of Common Stock which he would have owned or have been entitled to
receive immediately following any of the events described above had such
Warrant been exercised in full immediately prior to any such event. An
adjustment made pursuant to this Subsection shall, in the case of a
dividend in Common Stock, become effective as of the record date therefor
and, in the case of a subdivision or combination, be made as of the
effective date thereof. If, as a result of an adjustment made pursuant to
this subsection, the Holder of any Warrant thereafter surrendered for
exercise shall become entitled to receive Common Stock together with one or
more other interests in the Company, the Company and the Holder shall
determine the allocation of the adjusted Purchase Price between or among
such Common Stock and such interests.
12
<PAGE>
B. In the event of any adjustment of the total number of shares of
Common Stock purchasable upon the exercise of the then outstanding Warrants
pursuant to Subsection A above, the Purchase Price per share applicable to
each such outstanding Warrant shall be adjusted to be the amount resulting
from dividing the number of shares of Common Stock (including fractional
shares) covered by such Warrant immediately after such adjustment into the
total amount payable upon exercise of such Warrant in full immediately
prior to such adjustment.
C. In case the Company shall issue rights or warrants to all holders
of Common Stock entitling them (for a period expiring within 45 days after
the record date mentioned below) to subscribe for or purchase Common Stock
at a price per share less than the average market value at the closing
price for 20 consecutive trading days ending on the trading date
immediately preceding the issue date ("Average Market Value"), the Purchase
Price shall be adjusted so that the same shall equal the price determined
by multiplying the Purchase Price in effect immediately prior thereto by a
fraction, or which the numerator shall be the number of shares of Common
Stock outstanding on the record date plus the number of additional shares
which the aggregate offering price of the total number of shares offered
for subscription or purchase would purchase at such Average Market Value
per share, and of which the denominator shall be the number of shares
outstanding on such record date plus the number of shares offered for
subscription or purchase. Such adjustments shall be made whenever such
rights or warrants are issued, and shall become effective as of the record
date for the determination of shareholders entitled to receive such rights
or warrants.
D. In the event of any capital reorganization or any reclassification
of the Common Stock (except as provided in Subsection (A) above or
Subsection (H) below) any Holder of Warrants upon exercise thereof, shall
be entitled to receive, in lieu of the Common Stock to which he would have
become entitled upon exercise immediately prior to reorganization or
reclassification, the Shares of Common Stock, or other interests of the
Company or property of the Company that he would have been entitled to
receive at the same aggregate Purchase Price upon such reorganization or
reclassification if his Warrants had been exercised immediately prior
thereto; and in any such case, appropriate provision shall be made for the
application of this Section 4 with respect to the rights and interests
thereafter of the Holders of Warrants (including but not limited to the
allocation of the adjusted Purchase Price between or among the shares of
Common Stock and any other interests in the Company, to the end that this
Section 4 (including the adjustments of the number of shares of Common
Stock or other interests in the Company purchasable and the Purchase Price
thereof) shall thereafter be reflected, as nearly as reasonably
practicable, in all subsequent exercises of the Warrants for any shares of
Common Stock or other interests in the Company, or other property,
thereafter deliverable upon the exercise of the Warrants.
13
<PAGE>
E. In case the Company shall at any time issue or sell any shares of
Common Stock (including shares held in the Company's treasury but not
including shares issued or distributed as provided in subsection A of this
Section 4) for a consideration per share less than the Purchase Price in
effect immediately prior to the issuance or sale of such shares or without
consideration, then, and thereafter successively upon each such issuance or
sale, the Purchase Price in effect immediately prior to the issuance or
sale of such shares shall forthwith be reduced to a price (calculated to
the nearest full cent) determined by dividing:
(i) an amount equal to the sum of (A) the total number of shares
of Common Stock outstanding immediately prior to such issuance or sale
multiplied by the Purchase Price in effect immediately prior to such
issuance or sale and (B) the consideration, if any, received by the
Company upon such issuance or sale, by
(ii) the total number of shares of Common Stock outstanding
immediately after such issuance or sale.
For the purposes of any computation to be made in accordance with the
provisions of this subsection E the following provisions shall be
applicable:
(a) In case of the issuance or sale of shares of Common
Stock for cash, the consideration received by the Company
therefor shall be deemed to be the gross cash proceeds received
by the Company for such shares before deducting commissions or
other expenses paid or incurred by the Company for any
underwriting of, or otherwise in connection with the, issuance or
sale of such shares.
(b) In case of the issuance or sale of shares of Common
Stock for a consideration other than cash or a consideration a
part of which shall be other than cash, the amount of the
consideration other than cash received by the Company for such
shares shall be deemed to be the value of such consideration as
determined in good faith by the Board of Directors of the
Company.
(c) The number of shares of Common Stock at any time
outstanding shall not include any shares then owned or held by or
for the account of the Company.
F. No adjustment in the Purchase Price under this Section 4 shall be
made unless such adjustment would require an increase or decrease of at
least one percent in the Purchase Price; provided, however, that any
adjustments which by reason of this subsection are not required to be made
shall be carried forward and taken into account in any subsequent
adjustment. All calculations under this Section 4 shall be made to the
nearest cent or to the nearest one-hundredth of a share as the case may be.
14
<PAGE>
G. Whenever the number of shares of Common Stock or other securities
purchasable upon exercise of a Warrant or the Purchase Price is adjusted as
provided in this Section 4, the Company will promptly file with the Holder
a certificate signed by the President or Executive Vice President and by
the Secretary or an Assistant Secretary of the Company setting forth the
number and kind of shares of Common Stock or other interests in the Company
purchasable and the Purchase Price, as so adjusted, stating that such
adjustments in the number of shares of Common Stock or number or kind of
other interests in the Company, or in the Purchase Price, conform to the
requirements of this Section 4, and setting forth a brief statement of the
facts accounting for such adjustments. Promptly after receipt of such
certificate, the Company will mail a brief summary thereof to the Holder;
provided, however, that failure to file or to give any notice required
under this Subsection, or any defect therein, shall not affect the legality
or validity of any such adjustments under this Section 4.
H. In case of any consolidation of the Company with, or merger of the
Company with, or merger of the Company into, another corporation or other
entity (other than a consolidation or merger which does not result in any
reclassification or change of the outstanding shares of Common Stock), or
in case of any sale or conveyance to another entity of the property of the
Company as an entirety or substantially as an entirety, the corporation or
other entity formed by such consolidation or merger or the entity which
shall have acquired such assets, as the case may be, shall execute and
deliver to the Holder a supplemental warrant providing that the Holder
shall have the right thereafter (until the expiration of such Warrant) to
receive, upon exercise of such Warrant, the kind and amount of interests
and other securities and property receivable upon such consolidation,
merger, sale or transfer by a Holder of the number of shares of Common
Stock for which such Warrant might have been exercised immediately prior to
such consolidation, merger, sale or transfer. Such supplemental warrant
shall provide for adjustments which shall be as nearly equivalent as may be
practicable to the adjustments provided in this Section. The above
provision of this Subsection shall similarly apply to successive
consolidations, mergers, sales or transfers.
I. Irrespective of any adjustments in the Purchase Price or in the
number of kind of interests in the Company issuable upon exercise of
Warrants, Warrant Certificates theretofore or thereafter issued may
continue to express the same price and number and kind of interests as are
stated in the similar Warrant Certificates initially issuable pursuant to
this Warrant.
J. The Company may retain a firm of independent public accountants of
recognized standing, which may be the firm regularly retained by the
Company, selected by the Board of Directors of the Company and not
disapproved by the Holder, to make any computation required under this
Section, and a certificate signed by such firm shall be conclusive evidence
of the correctness of any computation made under this Section.
15
<PAGE>
5. Limited Rights of Holder. This Warrant does not entitle the Holder to
any voting rights or other rights as a shareholder of the Company, or to any
other rights whatsoever except the rights herein expressed. No dividends are
payable or will accrue on this Warrant or the shares purchasable hereunder
until, and except to the extent that, this Warrant is exercised.
6. Exchange for Other Denominations. This Warrant is exchangeable, on its
surrender by the registered owner to the Company, for new Warrants of like tenor
and date representing in the aggregate the right to purchase the number of
shares purchasable hereunder in denominations designated by the registered owner
at the time of surrender.
7. Transfer. Holder acknowledges that this Warrant and the shares of Common
Stock or other securities into which this Warrant is exercisable have not been
registered under the Securities Act or the Georgia Securities Act of 1973, or
any other state securities laws, but have been and will be issued pursuant to
exemptions therefrom. Accordingly, Holder acknowledges and agrees that this
Warrant and the securities acquired by it upon exercise hereof may be
transferred or assigned to another party only in accordance with a valid
registration statement or an exemption from registration under the Securities
Act and any applicable state securities laws.
Subject to applicable securities laws, this Warrant and all rights
hereunder are transferable by the Holder hereof in person or by duly authorized
attorney on the books of the Company upon surrender of this Warrant at the
principal offices of the Company, together with the Form of Assignment attached
hereto as Exhibit B duly executed. Absent any such transfer, the Company may
deem and treat the registered Holder of this Warrant at any time as the absolute
owner hereof for all purposes and shall not be affected by any notice to the
contrary.
8. Recognition of Registered Owner. Prior to due presentment for
registration of transfer of this Warrant, the Company may treat the registered
owner as the person exclusively entitled to receive notices and otherwise to
exercise rights hereunder.
9. Notice and Effect of Dissolution, etc. In case of a voluntary or
involuntary dissolution, liquidation, or winding up of the Company (other than
in connection with the consolidation or merger covered by Section 4 above) is at
any time proposed, the Company shall give at least 30 days' prior written notice
to the Holder. Such notice shall contain: (1) the date on which the transaction
is to take place; (2) the record date (which shall be at least 30 days after the
giving of the notice) as of which holders of Common Shares will be entitled to
receive distributions as a result of the transaction; (3) a brief description of
the transaction; (4) a brief description to be made to the holders of Common
Shares as a result of the transaction; and (5) an estimate of the fair value of
the distributions. On the date of the transaction, it if actually occurs, this
Warrant and all rights hereunder shall terminate.
16
<PAGE>
10. Method of Giving Notice; Extent Required. Notices shall be given by
certified first class mail, postage prepaid, addressed to the Holder at the
address of the owner appearing in the records of the Company or to the Company
at its principal office, or at such other addresses as to which either the
Holder or the Company gives the other written notice as provided herein.
Witness the seal of the Company and the signatures of its authorized
officers.
MEDICAL RESOURCE COMPANIES OF AMERICA
By:/s/ Gene S. Bertcher
Gene S. Bertcher, Executive Vice President
17
<PAGE>
EXHIBIT A
FORM OF ELECTION TO PURCHASE
(To be Executed by the Holder if He Desires to Exercise Warrants Evidenced
by the Within Warrant Certificate)
To MEDICAL RESOURCE COMPANIES OF AMERICA:
The undersigned hereby irrevocably elects to exercise Warrants evidenced by
the within Warrant Certificate for, and to purchase thereunder,
________________________ full Shares of Medical Resource Companies of America,
Common Stock issuable upon exercise of said Warrants and delivery of $2.64 for
each share purchased.
(name of holder)
By:
Title:
TAXPAYER IDENTIFICATION NUMBER:
If said number of Warrants shall not be all the Warrants evidenced by the
within Warrant Certificate, the undersigned requests that a new Warrant
Certificate evidencing the Warrants not so exercised by issued in the name of
and delivered to
- -----------------------------------------------------------------
(Please Print Name and Address)
- -----------------------------------------------------------------
- -----------------------------------------------------------------
18
<PAGE>
Dated:________________, 19____ Signature:
19
<PAGE>
EXHIBIT B
FORM OF ASSIGNMENT
(To be executed by the registered holder if he desires to assign warrants
evidenced by the within warrant certificate. Any such assignment is subject to
certain restrictions contained in the Warrant Certificate.)
FOR VALUE RECEIVED _____FFP Partnership, LP_________________ hereby sells,
assigns and transfers unto ________________________ Warrants to purchase
_540,000_ shares of Common Stock, par value $0.01 per share, of Medical Resource
Companies of America, evidenced by the within Warrant Certificate, and does
hereby irrevocably constitute and appoint _____________________, Attorney to
transfer the said Warrants evidenced by the within Warrant Certificate on the
books of the Company, with full power of substitution.
Dated: 10/10, 1995.
Judith L. Fowler
Arthur G. Weiss
20
<PAGE>
